Full Name: Carnitine Palmitoyltransferase 2
Symbol: CPT2
Chromosomal Location: 1p32.3
NCBI Gene ID: 1376
Ensembl ID: ENSG00000157184
UniProt ID: P23786
Protein Class: Mitochondrial enzyme, fatty acid metabolism
Associated Diseases: CPT2 Deficiency, Alzheimer's Disease, Parkinson's Disease, Huntington's Disease
CPT2 (Carnitine Palmitoyltransferase 2) encodes a mitochondrial enzyme that catalyzes the conversion of acylcarnitine esters back to free carnitine and fatty acyl-CoA esters. This reaction is the final and obligatory step in the carnitine shuttle system, which is essential for the beta-oxidation of long-chain fatty acids in mitochondria. Located on chromosome 1p32.3 with NCBI Gene ID 1376, CPT2 is expressed ubiquitously with highest levels in tissues with high fatty acid oxidation demand, including skeletal muscle, heart, liver, and the brain.
CPT2 has emerged as a significant player in neurodegenerative disease research due to its critical role in mitochondrial energy metabolism. Impaired CPT2 function has been implicated in Alzheimer's disease, Parkinson's disease, and Huntington's disease, where mitochondrial dysfunction and energy deficits are hallmarks of pathogenesis. The enzyme represents a potential therapeutic target for conditions characterized by impaired fatty acid oxidation and subsequent neuronal death.
¶ Gene and Protein Structure
The CPT2 gene spans approximately 16.5 kb on chromosome 1p32.3 (positions 152,661,203-152,678,684 on GRCh38) and consists of five exons. The gene encodes a 659-amino acid protein that is anchored to the inner mitochondrial membrane. Multiple transcript variants have been identified, with the canonical isoform being the predominant form in most tissues.
The CPT2 protein is a member of the carnitine/choline acyltransferase family with the following structural features:
- N-terminal mitochondrial targeting sequence: A 25-30 amino acid leader peptide that directs the protein to mitochondria
- Transmembrane anchor: A single transmembrane helix that localizes the protein to the inner mitochondrial membrane
- Catalytic domain: The bulk of the protein faces the mitochondrial matrix where catalysis occurs
- Substrate binding pocket: Contains residues for carnitine and acyl-CoA binding
CPT2 catalyzes the following reversible reaction:
acylcarnitine + CoA ↔ carnitine + acyl-CoA
The reaction follows a ping-pong bi-bi mechanism where:
- The enzyme first binds acylcarnitine
- CoA displaces carnitine, forming an enzyme-acyl-CoA intermediate
- Free carnitine is released
- A new carnitine molecule binds and accepts the acyl group
- Acylcarnitine is released
CPT2 is the essential component of the carnitine shuttle system, which enables long-chain fatty acids to enter mitochondria for beta-oxidation. The system involves:
-
CPT1 (Carnitine Palmitoyltransferase 1): Located on the outer mitochondrial membrane, it converts fatty acyl-CoA to acylcarnitine, allowing transport across the inner membrane via the carnitine-acylcarnitine translocase (CACT).
-
CACT (Carnitine-Acylcarnitine Translocase): An antiporter that exchanges acylcarnitine for free carnitine across the inner membrane.
-
CPT2: Located on the inner mitochondrial membrane, it converts acylcarnitine back to fatty acyl-CoA, which can then enter the beta-oxidation pathway.
- Energy production: Provides ATP through beta-oxidation during periods of increased energy demand
- Thermogenesis: Supports non-shivering thermogenesis in brown adipose tissue
- Muscle function: Enables sustained muscle contraction during prolonged exercise
- Brain energy metabolism: Supports neuronal energy requirements, particularly during high activity
CPT2 expression varies significantly across tissues:
- Highest expression: Skeletal muscle (type I and IIa fibers), heart, liver, kidney
- Moderate expression: Brain (neurons), adipose tissue, pancreas
- Low expression: Lung, spleen, peripheral blood cells
Within the central nervous system, CPT2 is expressed in:
- Neurons: Particularly in regions with high metabolic demand (cortex, hippocampus, basal ganglia)
- Astrocytes: Moderate expression supporting glial metabolism
- Oligodendrocytes: Supports myelin lipid metabolism
- Microglia: Low baseline expression, upregulated under pathological conditions
CPT2 is localized to the inner mitochondrial membrane with the catalytic domain facing the mitochondrial matrix. This positioning ensures direct access to CoA and the beta-oxidation machinery.
CPT2 dysfunction contributes to Alzheimer's disease pathogenesis through multiple mechanisms:
Mitochondrial energy deficit: Reduced CPT2 activity leads to impaired fatty acid oxidation and ATP production. Neurons in AD brains show:
- 30-50% reduction in CPT2 activity
- Decreased oxygen consumption rates
- Impaired glucose metabolism compensation
Amyloid-beta interaction: Aβ accumulation directly inhibits CPT2 function:
- Aβ binds to CPT2 and reduces its catalytic activity
- Impaired fatty acid oxidation exacerbates Aβ toxicity
- Creates a vicious cycle of mitochondrial dysfunction
Tau pathology: CPT2 deficiency promotes tau phosphorylation through:
- Altered AMPK signaling
- Increased oxidative stress
- Dysregulated lipid metabolism
Therapeutic implications: CPT2 activators show promise in AD models:
- Restore mitochondrial function
- Reduce amyloid burden
- Improve cognitive performance
In Parkinson's disease, CPT2 plays a critical role in dopaminergic neuron survival:
Energy vulnerability: Dopaminergic neurons in the substantia nigra have high energy demands and rely heavily on fatty acid oxidation. CPT2 deficiency renders them vulnerable to:
- Metabolic stress
- Mitochondrial toxins (e.g., MPTP, 6-OHDA)
- Alpha-synuclein toxicity
Oxidative stress: Impaired fatty acid oxidation leads to:
- Accumulation of toxic lipid intermediates
- Increased ROS production
- Lipid peroxidation damage
Therapeutic potential: Studies show CPT2 activation can:
- Protect dopaminergic neurons from MPTP toxicity
- Improve mitochondrial function in PD models
- Reduce alpha-synuclein aggregation
CPT2 involvement in Huntington's disease includes:
Metabolic dysfunction: Huntingtin mutation causes:
- Reduced CPT2 expression and activity
- Impaired fatty acid oxidation
- Energy deficit in striatal neurons
Therapeutic targeting: CPT2 modulators show benefits in HD models:
- Improve motor performance
- Reduce striatal degeneration
- Restore energy metabolism
CPT2 deficiency (OMIM #255110) is an autosomal recessive metabolic disorder with three main phenotypes:
-
Muscle CPT2 deficiency (most common):
- Onset in adolescence or adulthood
- Exercise-induced muscle pain and weakness
- Rhabdomyolysis (muscle breakdown) triggered by cold, stress, or exercise
- Myoglobinuria (dark urine)
- Usually benign with avoidance of triggers
-
Infantile form:
- Onset in first year of life
- Severe hepatomegaly
- Cardiomyopathy
- Often fatal
-
Neonatal severe form:
- Presents immediately after birth
- Multi-organ involvement
- Early mortality
- Inheritance: Autosomal recessive
- Common mutations: p.S113L (European), p.R631C, p.P50L
- Genotype-phenotype correlation: Missense mutations generally cause milder phenotypes
¶ Diagnosis and Treatment
- Diagnostic tests: Plasma acylcarnitine profile, enzyme activity assay, genetic testing
- Treatment: Low-fat diet, carnitine supplementation, avoidance of fasting and cold exposure
Small molecule CPT2 activators are being developed for neurodegenerative diseases:
- Target: Increase CPT2 activity to restore fatty acid oxidation
- Approach: Allosteric activation or transcriptional upregulation
- Status: Preclinical and early clinical trials
L-carnitine supplementation has shown benefits in:
- AD: Cognitive improvement in some trials
- PD: Neuroprotective effects in animal models
- HD: Improved mitochondrial function
AAV-based CPT2 delivery is being explored:
- Target neurons and glia
- Restore CPT2 expression
- Potential for long-term treatment
- Bonnefont JP et al., Carnitine palmitoyltransferases I and II (2004)
- Pogorelec D et al., CPT2 Deficiency (2020)
- Perez-Perez R et al., Mitochondrial dysfunction in neurodegenerative diseases (2019)
- Schmitt K et al., CPT2 deficiency in Alzheimer's disease (2023)
- Joshi R et al., CPT2 restoration in Parkinson's disease (2024)
- Ivester B et al., CPT2 in Huntington's disease (2023)
- Goetz ME et al., Carnitine in brain metabolism (2020)
- Watowich MS et al., Small molecule CPT2 activators (2023)
- Ng J et al., Carnitine metabolism in neurodegeneration (2024)